TheraRadar
Home/Indications/Respiratory/Allergic Rhinitis

Allergic Rhinitis

Respiratory 1 original drugs
1
Novel Drugs
9
Reformulations
35
Active Trials
4
Drug Targets

Phase 3 Readouts Pro

6 active Phase 3 trials with confidence-graded completion dates.

Full calendar →
Q2 2026
3,000 MM09
Inmunotek S.L.
Estimated · stale NCT05641272
Q2 2026
PG-011 nasal spray 0.6%(twice daily)
Prime Gene Therapeutics Co., Ltd.
Estimated · aging NCT07146126
Q3 2026
HDM SLIT-tablet (12 SQ-HDM)
ALK-Abelló A/S
Estimated · fresh NCT07060885
Unlock 3 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 9 mechanisms across 20 industry trials with a known mechanism of action.

See full pipeline →
Glucocorticoid receptor
4 trials 4 sponsors
Beta-2 adrenergic receptor/Glucocorticoid receptor
3 trials 3 sponsors
H1-receptor
3 trials 2 sponsors
H1 receptor
3 trials 3 sponsors
Corticosteroid
2 trials 2 sponsors
Anti-IgE
2 trials 2 sponsors
Glucocorticoid receptor/Histamine H1 receptor
1 trials 1 sponsor
Interleukin-4 Receptor alpha Antagonist
1 trials 1 sponsor
Nonsteroidal Anti-inflammatory Drug
1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

266 industry-sponsored trials across 115 sponsors

View full landscape →

Novel Drugs by Company (New molecular entities)

Reformulations (9 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Generic Drugs (9 ANDA approved) Click to expand

Related Indications

Other Respiratory indications

Drug Categories:

  • Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
  • Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
  • Biosimilars: BLA-approved biologics highly similar to reference products
  • Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology